| Finished Dosage Formulations | Domestic and international branded generics, ethicals, generics, and own-brand pharmaceuticals. | Strong regulatory approvals, established customer base, and robust distribution network. | Pharmacies, hospitals, doctors, healthcare providers in domestic and global markets (B2B and B2C). | Ethical and own-brand finished dosage with higher gross margins. | 40000 | 71 | Sales of pharmaceutical formulations through direct marketing and distributor networks. | Product sales with focus on value, volume growth, and brand presence. | Expanding exports, regulatory approvals, and new product additions. | Clarithromycin, Atorvastatin, Fexofenadine, Metformin, Aripiprazole |
| Contract Manufacturing and Out-Licensing (CMO) | Contract manufacturing of pharmaceutical products and out-licensing of formulations. | Regulatory accreditations and long-standing client relationships. | Global pharma companies in regulated markets (B2B). | Long-term supply contracts and complex formulations. | 14000 | 25 | Manufacturing contracts, licensing fees, and supply agreements. | Contractual manufacturing revenue with steady contract terms. | Increasing outsourcing by global pharma, capacity expansions, and regulatory compliance. | Manufacturing partnerships with Viatris, Chanelle, Wockhardt |
| Domestic Generics and Others | Generics and other pharma products for domestic distribution. | Pan-India presence through extensive stockist network. | Pharmacies, hospitals, and retailers across India (B2B and B2C). | Ethical and branded generics. | 1600 | 4 | Sales to distributors and wholesalers within India. | Volume-based sales with competitive pricing. | Growing domestic pharma demand and chronic disease prevalence. | Various generic products supplied to Indian market |
